Entity
  • Nova In Silico

    Created in 2010
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    532 4,753
  • Activities

  • Technologies

  • Entity types

  • Location

    1 Pl. Giovanni da Verrazzano, 69009 Lyon, France

    Lyon

    France

  • Employees

    Scale: 51-200

    Estimated: 59

  • SIREN

    521885368
  • Engaged corporates

    18
    7 11
  • Added in Motherbase

    6 years, 3 months ago
Description
  • Value proposition

    Nova has built jinkō, a unique in silico clinical trial simulation platform to de-risk and accelerate clinical trials

    Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations.

    Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials.

    Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

    Pharmaceutical R&D, Computer Sciences, In silico clinical trials, Clinical pharmacology , QSP, PK/PD, Quantitative clinical pharmacology, Systems biology, and Pharmacometrics

  • Original language

    Nova has built jinkō, a unique in silico clinical trial simulation platform to de-risk and accelerate clinical trials

    Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations.

    Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials.

    Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

Corporate interactions BETA
Corporate TypeTweets Articles
Medicen Paris Region
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Other

9 Jun 2023


Capgemini
Capgemini
Consulting, IT Services and IT Consulting
Capgemini
Consulting, IT Services and IT Consulting
Other

3 Jul 2023


SATT Sud-Est
SATT Sud-Est
Research, National and local authorities, Research Services
SATT Sud-Est
Research, National and local authorities, Research Services
Other

11 May 2024


Amazon Web Services (AWS)
Amazon Web Services (AWS)
IT services, IT Services and IT Consulting
Amazon Web Services (AWS)
IT services, IT Services and IT Consulting
Other

4 Apr 2023


Takeda
Takeda
Pharmaceutical, Pharmaceutical Manufacturing
Takeda
Pharmaceutical, Pharmaceutical Manufacturing
Other

3 Mar 2023


Novartis
Novartis
Pharmaceutical, Pharmaceutical Manufacturing
Novartis
Pharmaceutical, Pharmaceutical Manufacturing
Other

3 Apr 2023


EY Pythagoras
EY Pythagoras
IT Services and IT Consulting
EY Pythagoras
IT Services and IT Consulting
Other

20 May 2015


Johnson & Johnson
Johnson & Johnson
Pharmaceutical, Hospitals and Health Care
Johnson & Johnson
Pharmaceutical, Hospitals and Health Care
Not capitalistic
Partnership
Not event

16 Dec 2021


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Other

19 Jan 2021

17 Oct 2024



Sanofi
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Capitalistic
Partnership
Event

19 Jun 2021

1 Nov 2024



Similar entities
Loading...
Loading...
Social network dynamics